These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 2507799)

  • 21. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [In vitro antibacterial activity of a new parenteral penem, sulopenem].
    Yoshida T; Tateda E; Hiramatsu K; Yokota T
    Jpn J Antibiot; 1996 Apr; 49(4):324-37. PubMed ID: 8786624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro antibacterial activities of cefteram and other beta-lactam agents against recent clinical isolates].
    Yamaguchi K; Ohno A; Takahashi S; Hayashi M; Yamanaka K; Hirakata Y; Mitsuyama J
    Jpn J Antibiot; 1998 Jan; 51(1):11-25. PubMed ID: 9557273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1984). III. Secular changes in susceptibility].
    Kosakai N; Kumamoto Y; Sakai S; Hirose T; Shigeta S; Shiraiwa Y; Miura Y; Ogata M; Tazaki H; Iri H
    Jpn J Antibiot; 1986 Nov; 39(11):3019-93. PubMed ID: 3102809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antibacterial activity of cefmenoxime against clinical isolates. Comparative study].
    Takahashi C; Miyazawa K
    Jpn J Antibiot; 1985 Jan; 38(1):27-30. PubMed ID: 3886949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Susceptibilities of clinical isolates to antibacterial agents. A study mainly focused on ofloxacin (the second report). Reported by the Research Group for Testing ofloxacin Susceptibility on Clinical Isolates].
    Kosakai N
    Jpn J Antibiot; 1989 May; 42(5):1125-65. PubMed ID: 2664255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Distribution and drug-resistance of 3 500 gram-negative bacteria in Guangzhou].
    Xiao QZ; Su DH; Jiang JH; Zhong NS
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Feb; 25(2):132-8. PubMed ID: 15698988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium].
    Daimon Y
    Jpn J Antibiot; 1990 Nov; 43(11):1948-55. PubMed ID: 2287059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Susceptibilities of clinical isolates to antibacterial agents. Focusing mainly on ofloxacin (first report). Reported by the Research Group for Testing Ofloxacin Susceptibility of Clinical Isolates].
    Kosakai N
    Jpn J Antibiot; 1988 Jan; 41(1):71-104. PubMed ID: 3163383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Survey of sensitivities of clinical isolates to antibacterial agents (annual report)].
    Igari J; Inoue M; Nishino T; Watanabe N; Uehara N; Yoshida H; Imafuku Y; Shibano T; Satou S; Kobayashi I; Takahashi A; Yomoda S; Oguri T; Kumasaka K; Okada J; Hirata Y; Uchida K; Kawaguchi R; Ohtaki Y; Ishigo S; Okamoto E; Murakami E; Matsuoka K; Tokuda K; Saeki H
    Jpn J Antibiot; 1997 Aug; 50(8):683-703. PubMed ID: 9339395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--II. Gram-negative bacteria].
    Suzuki Y; Nishinari C; Endo H; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Aug; 56(4):309-35. PubMed ID: 14567255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antimicrobial susceptibility and beta-lactamase types among clinical isolates during January and February 2000 in the Kinki area of Japan].
    Yamasaki K; Nishio H; Komatsu M; Satoh K; Yamashita T; Washidu R; Shimakawa K; Kinoshita S; Ura T; Aihara M
    Jpn J Antibiot; 2002 Sep; 55 Suppl A():65-78. PubMed ID: 12599530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)].
    Igari J; Inoue M; Nishino T; Watanabe N; Uehara N; Yoshida H; Imafuku Y; Shibano T; Satou S; Kobayashi I; Takahashi A; Yomoda S; Oguri T; Kumasaka K; Kobayasi Y; Okada J; Hirata Y; Nakasaki N; Kawaguchi R; Ohtaki Y; Ishigo S; Okamoto E; Murakami E; Matsuoka K; Saeki H
    Jpn J Antibiot; 1998 Feb; 51(2):47-68. PubMed ID: 9575436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of the antibacterial activity in vitro of various cephalosporins on different gram-negative bacterial species of recent clinical isolation].
    Piccolomini R; Di Sipio L; Ravagnan G
    Boll Soc Ital Biol Sper; 1980 Jan; 56(2):133-9. PubMed ID: 6776969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antimicrobial susceptibility and prevalence of beta-lactamase producing clinical isolates in southern Kyushu. The results of collaborative study from 1999 to 2000].
    Nakasone I; Onaga S; Fukunaga H; Saitoh H; Yamane N; Sato Y
    Jpn J Antibiot; 2002 Sep; 55 Suppl A():95-110. PubMed ID: 12599533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1984). I. Susceptibility distribution].
    Kosakai N; Kumamoto Y; Sakai S; Hirose T; Shigeta S; Shiraiwa Y; Miura Y; Ogata M; Tazaki H; Iri H
    Jpn J Antibiot; 1986 Nov; 39(11):2959-3006. PubMed ID: 3102808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
    Hamouche E; Sarkis DK
    Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antimicrobial activity of cefodizime against clinical isolates].
    Suzuki Y; Ishihara R; Ishii Y; Nakazawa A; Deguchi K; Matsumoto Y; Nishinari C; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1996 Oct; 49(10):947-65. PubMed ID: 8986558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.